Immunology Clinical Trials Update: Week 15, 2026

Published April 10, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert

Biologics in Chronic Rhinosinusitis With Nasal Polyposis

This Phase 4 trial from the Medical University of South Carolina is exploring biologic medications for adults living with chronic sinusitis and nasal polyps. The study aims to determine which biologic treatment works best and whether specific biomarkers can help predict how patients will respond. If successful, this research could lead to more personalized treatment plans that better target each patient’s condition.

Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy

ARS Pharmaceuticals is conducting a Phase 4 study to test the safety and effectiveness of Neffy, a needle-free epinephrine delivery system, compared to traditional intramuscular adrenaline. This study focuses on patients who experience allergic reactions after food challenges or allergen immunotherapy. Positive results may provide a simpler and potentially less intimidating option for managing severe allergic reactions that require epinephrine treatment.

Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients

The University of California, Davis is studying whether adjusting immunosuppressive medications can improve the immune response to a third dose of COVID-19 mRNA vaccine in kidney transplant recipients. People with organ transplants often have weaker responses to vaccines, so this research could help protect them better against COVID-19. The trial is active but not recruiting, with results expected after completion.

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

This Phase 1 trial by Allogene Therapeutics is testing a new type of treatment called ALLO-329, which uses engineered immune cells to target autoimmune diseases such as lupus, inflammatory myopathy, and systemic sclerosis. The study aims to establish whether this therapy is safe and shows early signs of benefit. If successful, it could offer a new treatment option that more precisely controls immune system activity in these conditions.

Food Oral Immunotherapy for Peanut Allergy

Massachusetts General Hospital is conducting a study to evaluate food oral immunotherapy for people with peanut allergy, ranging in age from six months to 65 years. This approach involves gradually introducing peanut proteins to build tolerance and reduce allergic reactions. The study includes biomarker samples and questionnaires to better understand how patients respond to this treatment method.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.